Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015 – Genetic Engineering & Biotechnology News
CNBC |
Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II … Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drug Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback Juno ends flagship drug trial after deaths and FDA suspensions |
